CTOs on the Move

StriVectin

www.strivectin.com

 
Our mission is simple. Deliver the most high-performance skincare and haircare solutions powered by the latest clinical advances to transform the look of your skin and hair. At the center of every formula is patented, proprietary NIA-114 technology that supercharges StriVectin`s clinically proven, award winning products.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.strivectin.com
  • 601 West 26th Street Suite 1505
    New York, NY USA 10001
  • Phone: 800.430.0227

Executives

Name Title Contact Details

Similar Companies

The HealthCare Chaplaincy

The HealthCare Chaplaincy Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. The HealthCare Chaplaincy Inc. is based in New York, NY. You can find more information on The HealthCare Chaplaincy Inc. at www.healthcarechaplaincy.org

Unicity International

Unicity International is a Orem, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Garden of Life, Inc.

Garden of Life, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in West Palm Beach, FL. To find more information about Garden of Life, Inc., please visit www.gardenoflife.com

E P Radiological Svc

E P Radiological Svc is a Canoga Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.